Hyperkalaemia — ESENeph MCQ
Instant feedback + full explanation. One question, done properly.
Educational content. Not a substitute for clinical judgement or local policy.
Reveal the answer and explanation
Correct answer: D — Spironolactone
In the context of hyperkalaemia with ECG changes, the drug most likely to be contributing and the least evidence-based for renal protection in this scenario is Spironolactone (steroidal MRA). RASi and SGLT2i have strong evidence for slowing CKD progression and should be maintained if possible. KDIGO 2024 emphasises continuing ACEi/ARB even when eGFR falls below 30. SGLT2i has kidney-protective benefit. Spironolactone lacks the outcome data of finerenone in CKD and is the appropriate medication to discontinue first.
Reference: KDIGO 2024 – Clinical Practice Guideline for CKD; NICE CG182 2024 update